Btla

BTLA (B and T Lymphocyte Attenuator) is a cell surface receptor protein that plays a crucial role in regulating the immune system. BTLA belongs to the CD28 immunoglobulin superfamily and includes an extracellular immunoglobulin-like domain, a transmembrane region, and an intracellular signaling domain. BTLA serves as an immune checkpoint molecule responsible for modulating immune responses. When BTLA interacts with its ligand HVEM (Herpes Virus Entry Mediator), it can inhibit the activation of T cells, dampen the immune response, and thereby contribute to maintaining immune balance. In cancer therapy, researchers are exploring ways to enhance the immune response of T cells against tumor cells by intervening in the interaction between BTLA and HVEM. Additionally, understanding the regulatory role of BTLA helps us gain a better understanding of the mechanisms underlying autoimmune diseases and may provide new insights into the development of treatment approaches.

Popular Product

Recombinant Human B- and T-lymphocyte attenuator(BTLA),partial (Active) CSB-MP773799HU

Validated Data

SDS

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

ELISA

Activity: Measured by its binding ability in a functional ELISA. Immobilized BTLA at 5 μg/ml can bind biotinylated human TNFRSF14 (CSB-MP842173HU-A), the EC₅₀ is 137.8-233.4 ng/ml.